Literature DB >> 1332710

Na+/H(+)-antiporter activity is essential for the induction, but not the maintenance of osteoclastic bone resorption and cytoplasmic spreading.

T J Hall1, M Schaeublin, T J Chambers.   

Abstract

We have examined the kinetics of the effects of inhibitors of the Na+/H(+)-antiporter (dimethylamiloride) and the vacuolar H(+)-ATPase (bafilomycin A1) on bone resorption by disaggregated rat osteoclasts in the bone slice assay. Bafilomycin A1 (100 nM) inhibited resorption by approximately 95%, 75%, 80% and 60% respectively, when added at t = 0, 1, 3 or 6 hr after osteoclast adherence to bone slices, during a 24 hr culture period. The incomplete inhibition by bafilomycin A1 when added after the start of incubation was presumably accounted for by resorption that had occurred prior to addition of the compound. Dimethylamiloride (100 microM) inhibited bone resorption by 80% and 65% when added at t = 0 or 1 hr after osteoclast adherence, but was without effect when added at t = 3 or 6 hr. In addition, dimethylamiloride but not bafilomycin A1 strongly inhibited osteoclast cytoplasmic spreading. The results indicate that Na+/H(+)-antiporter activity is essential for controlling intracellular pH during early activation events stimulated by the adherence of osteoclasts to mineralized bone surfaces, which lead to cytoskeletal activation, cell spreading and bone resorption.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332710     DOI: 10.1016/0006-291x(92)91344-p

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Molecular aspects of osteoclast function.

Authors:  T J Hall; T J Chambers
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

2.  Resorption-cycle-dependent polarization of mRNAs for different subunits of V-ATPase in bone-resorbing osteoclasts.

Authors:  T Laitala-Leinonen; M L Howell; G E Dean; H K Väänänen
Journal:  Mol Biol Cell       Date:  1996-01       Impact factor: 4.138

3.  The analgesic drug buprenorphine inhibits osteoclastic bone resorption in vitro, but is proinflammatory in rat adjuvant arthritis.

Authors:  T J Hall; B Jagher; M Schaeublin; I Wiesenberg
Journal:  Inflamm Res       Date:  1996-06       Impact factor: 4.575

4.  Taxol inhibits osteoclastic bone resorption.

Authors:  T J Hall; H Jeker; M Schaueblin
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

5.  Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, inhibits osteoclastic bone resorption in vitro.

Authors:  T J Hall; H Jeker; M Schaueblin
Journal:  Calcif Tissue Int       Date:  1995-04       Impact factor: 4.333

6.  Promethazine inhibits osteoclastic bone resorption in vitro.

Authors:  T J Hall; M Schaueblin
Journal:  Calcif Tissue Int       Date:  1994-07       Impact factor: 4.333

7.  Calcitonin inhibits proton extrusion in resorbing rat osteoclasts via protein kinase A.

Authors:  Hiroshi Kajiya; Fujio Okamoto; Hidefumi Fukushima; Koji Okabe
Journal:  Pflugers Arch       Date:  2003-01-14       Impact factor: 3.657

8.  Gold salts inhibit osteoclastic bone resorption in vitro.

Authors:  T J Hall; H Jeker; H Nyugen; M Schaeublin
Journal:  Inflamm Res       Date:  1996-05       Impact factor: 4.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.